The year 2024 has been considered the ‘coming of age’ era for antibody-drug conjugates, in great part due to the remarkable resurgence in drug development across the Asia-Pacific region. This part of the world is taking the ADC industry by storm with high-profile deals, multiple approvals, multiple ADCs moving into clinical trials, and novel targets being explored just to name some advancements.

Back by popular demand after a short break, the 3rd World ADC Asia is bringing together pioneers and key opinion leaders across mega-pharma and biotechnology focusing on China, Japan, Taiwan, South Korea and Singapore. They’ll be sharing their most pressing challenges, novel payloads, conjugation, and linker innovations to inform ADC development and improve targeting accuracy.

Alongside a phenomenal speaker faculty, our ADC Technical Lead and Researcher, Jia He, will be exploring the flourishing landscape. Taking time to review the clinical and preclinical space, and analyzing trends in this recent flurry of ADC deals, this is one not to be missed! Uncover the full presentation details today.